226 related articles for article (PubMed ID: 9829884)
1. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.
Etheridge SP; Tani LY; Minich LL; Revenaugh JR
Cathet Cardiovasc Diagn; 1998 Nov; 45(3):264-8. PubMed ID: 9829884
[TBL] [Abstract][Full Text] [Related]
2. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?
Williams RV; Wilke VM; Tani LY; Minich LL
Pediatrics; 2002 Jan; 109(1):E4. PubMed ID: 11773572
[TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
Rechavia E; Wurzel M
Circulation; 1998 Sep; 98(12):1249-50. PubMed ID: 9743517
[No Abstract] [Full Text] [Related]
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
EPISTENT Investigators
Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
8. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
9. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease.
Bachlava E; Loukopoulou S; Karanasios E; Chrousos G; Michos A
Int J Cardiol; 2016 Oct; 220():65-9. PubMed ID: 27372045
[TBL] [Abstract][Full Text] [Related]
10. A child with Kawasaki disease who survived after rupture of a coronary artery aneurysm.
Mok GC; Sung RY; Yam MC; Arifi AA; Lam WW; Fok TF
Eur J Pediatr; 2003 Sep; 162(9):634-6. PubMed ID: 12811552
[No Abstract] [Full Text] [Related]
11. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
Dangas G; Marmur JD; King TE; De Leon J; Sharma SK; Vidhun R; Feldman D; Stoynov MY; Badimon JJ; Ambrose JA
Am Heart J; 1999 Jul; 138(1 Pt 1):49-54. PubMed ID: 10385763
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
13. Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease.
Sivakumar K; Pavithran S
Pediatr Cardiol; 2013 Feb; 34(2):444-6. PubMed ID: 22427313
[TBL] [Abstract][Full Text] [Related]
14. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
15. Images in cardiovascular medicine. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor.
Rerkpattanapipat P; Kotler MN; Yazdanfar S
Circulation; 1999 Jun; 99(22):2965. PubMed ID: 10359744
[No Abstract] [Full Text] [Related]
16. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
18. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
Jone PN; Tapia D; Davidson J; Fagan TE; Browne L; Ing RJ; Kay J
Semin Cardiothorac Vasc Anesth; 2015 Sep; 19(3):255-9. PubMed ID: 25700695
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis.
Shetler TJ; Crowe VG; Bailey BD; Jackson CV
Circulation; 1996 Oct; 94(7):1719-25. PubMed ID: 8840866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
